Casemix-based budget impact analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anaemia in the Netherlands.

What To Know

This abstract reports a Dutch casemix budget-impact analysis comparing two intravenous iron formulations — ferric derisomaltose (FDI) and ferric carboxymaltose (FCM) — for treating iron deficiency anaemia (IDA) in people with inflammatory bowel disease (IBD).

Using hospital coding and tariff data over a 5-year horizon, the authors modelled treatment costs and related complication costs from the national health insurer perspective. The study found lower overall costs with FDI versus FCM.

Under full replacement of FCM by FDI in the eligible population, the analysis estimates annual savings of about €2.9 million on infusion costs alone, and up to €28.2 million when related costs and complications are included. The authors report sensitivity analyses that they say support the robustness of the result.

Limitations noted by the authors include potential underreporting in the Dutch DBC hospital coding system and a 5-year analytical time frame. This is a health-economics model using coded hospital data and not a randomized clinical trial; it assesses budget impact rather than clinical efficacy.